Lucence Diagnostics
Lucence Diagnostics is a privately held diagnostics company that develops ultrasensitive liquid biopsy tests (LiquidHALLMARK, LucenceINSIGHT, CardioHemeRISK) powered by its proprietary AmpliMARK platform for oncologists, patients, and healthcare institutions across the US, Singapore, Hong Kong, and Malaysia.
- Company typePrivate
- Founded2016
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Lucence Diagnostics does
Lucence Diagnostics is a privately held clinical diagnostics company founded in 2016 that develops and commercializes ultrasensitive liquid biopsy tests for cancer detection, treatment selection, and cardiovascular/leukemia risk assessment. The company's product portfolio includes LiquidHALLMARK® (and its CSF variant) for ctDNA and ctRNA-based tumor mutation profiling, LucenceINSIGHT® for multi-cancer early detection across up to 50 cancer types at 99% specificity (available internationally outside the USA), and CardioHemeRISK™ for clonal hematopoiesis mutation detection. All assays are powered by Lucence's proprietary AmpliMARK™ technology and, in the case of CardioHemeRISK, by mirror barcoding technology, enabling single-blood-draw genomic analysis for oncologists and patients.
The company operates a B2B2C go-to-market model, distributing tests primarily through physician-ordered laboratory processing, with a customer portal (lucence.my.site.com) for ordering and results, and additional channel reach via pathology partnerships in international markets such as Malaysia. Revenue is generated per assay through diagnostic testing services, supplemented by funded research collaborations such as the S$6 million UNITED 2.0 program with DxD Hub and NCCS. US clinical operations are supported by CAP and CLIA certifications, and the company maintains offices in Singapore (primary headquarters), Palo Alto, and Hong Kong. Strategic co-development partnerships with NCCS, DxD Hub, Quanterix, and Partners Pathology provide validation, geographic expansion, and emerging integration with adjacent biomarker technologies.
Lucence Diagnostics firmographics
Firmographics- Name
- Lucence Diagnostics
- Legal name
- Lucence Health Inc.
- Website
- https://lucencedx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lucence Diagnostics is a privately held diagnostics company that develops ultrasensitive liquid biopsy tests (LiquidHALLMARK, LucenceINSIGHT, CardioHemeRISK) powered by its proprietary AmpliMARK platform for oncologists, patients, and healthcare institutions across the US, Singapore, Hong Kong, and Malaysia.
- Ownership category
- akta.pro rank
Lucence Diagnostics industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Lucence Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Lucence Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: Lucence generates revenue through the sale of its liquid biopsy and NGS-based diagnostic tests (LiquidHALLMARK, CardioHEMEK, LucenceINSIGHT) ordered by physicians or healthcare institutions. Tests are billed per individual assay, with revenue driven by test volume and pricing per patient.
- International Test Services: The company serves international markets (outside USA) with its LucenceINSIGHT MCED test, generating revenue from international healthcare institutions and patients. Regional partnerships with pathology labs in Malaysia and other markets further extend test access.
- Research Collaboration Services: S$6 million research collaboration with DxD Hub and NCCS represents a funded R&D partnership model, providing revenue for co-development of advanced cancer profiling assays using AI and genomic sequencing technologies.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Lucence Diagnostics product offering
Product offeringCore offering
Lucence Diagnostics develops and commercializes ultrasensitive, non-invasive liquid biopsy diagnostic tests that analyze circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) from blood samples. Its portfolio supports cancer treatment selection (LiquidHALLMARK® and LiquidHALLMARK® CSF), multi-cancer early detection (LucenceINSIGHT®), and cardiovascular and leukemia risk evaluation through clonal hematopoiesis mutation detection (CardioHemeRISK™). All tests are powered by the company's proprietary AmpliMARK™ chemistry and mirror barcoding technology, processed through its CAP-accredited, CLIA-certified clinical laboratory.
Product overview
Lucence Diagnostics offers a portfolio of liquid biopsy-based diagnostic tests powered by its proprietary AmpliMARK™ technology. The core offerings include LiquidHALLMARK® (and its CSF variant) for ctDNA/ctRNA cancer mutation detection supporting treatment selection, LucenceINSIGHT® for multi-cancer early detection screening up to 50 cancers, and CardioHemeRISK™ for cardiovascular and leukemia risk evaluation through clonal hematopoiesis mutation detection. All products utilize blood-based testing with a single blood draw approach, enabling earlier detection and personalized treatment planning.
Differentiator
Problem solved
Functional benefit
Brands
- LiquidHALLMARK®: Ultra-sensitive liquid biopsy test that analyzes ctDNA and ctRNA to identify cancer-related mutations with a single blood draw.
- LiquidHALLMARK® CSF
- CardioHemeRISK™
- LucenceINSIGHT®
- AmpliMARK™
Products and services
- LiquidHALLMARK® Ultra-sensitive liquid biopsy test that analyzes both circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) from a single blood draw to identify cancer-related mutations and support treatment selection decisions. Powered by Lucence's proprietary AmpliMARK™ technology. Used by oncologists for personalized treatment planning and disease recurrence monitoring.
- LiquidHALLMARK® CSF Liquid biopsy test for cerebrospinal fluid (CSF) analysis, designed to support treatment selection decisions in neurological conditions using the same AmpliMARK™-powered approach as the blood-based LiquidHALLMARK® test.
- CardioHemeRISK™ Liquid biopsy-based NGS test that detects aging and lifestyle-related clonal hematopoiesis (CH) mutations using Lucence's proprietary mirror barcoding technology, supporting evaluation of hidden cardiovascular and leukemia risks for personalized preventive care.
- LucenceINSIGHT® Multi-cancer early detection (MCED) test that screens for up to 50 cancer types at 99% specificity using a single blood draw, enabling earlier cancer detection before symptoms appear. Available internationally outside the USA.
Quantifiable outcome
- 99% specificity across up to 50 cancer types screened with a single blood draw
- +1 more outcomes
Companies that use Lucence Diagnostics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Lucence Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Lucence Diagnostics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- DxD Hub (Diagnostics Development Hub)coreDxD Hub, together with Lucence and NCCS, launched UNITED 2.0 — a S$6 million research collaboration in Singapore to develop a more advanced AI-driven cancer profiling test using genomic sequencing technologies. The collaboration analyzes tumor and tissue samples for comprehensive genetic information to support precision cancer treatments and monitor disease recurrence. This is a flagship strategic co-development initiative for multiomic tumor profiling.
- NCCS (National Cancer Centre Singapore)coreNCCS, in partnership with Lucence and DxD Hub, launched UNITED 2.0 — a S$6 million research collaboration to develop an advanced multiomic tumor profiling assay using AI and genomic sequencing technologies. The assay aims to provide comprehensive genetic information to support precision cancer treatments and monitor disease recurrence.
- Partners PathologyminorLucence and Partners Pathology collaborate to advance cancer diagnostics in Malaysia. The partnership enables distribution and local accessibility of Lucence's diagnostic testing capabilities in the Malaysian market.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
Lucence Diagnostics competitors and assessment
Company assessmentDirect peers
- Guardant Health: Guardant Health is a leading US liquid biopsy company offering ctDNA-based oncology tests (Guardant360, Guardant Reveal for MRD). It is the closest direct competitor to Lucence's LiquidHALLMARK® and LucenceINSIGHT® in tumor profiling and minimal residual disease applications.
- GRAIL: GRAIL develops the Galleri multi-cancer early detection (MCED) test, directly competing with Lucence's LucenceINSIGHT® in the blood-based MCED category. Both target screening for multiple cancers from a single blood draw using proprietary methylation/ctDNA approaches.
- Natera: Natera offers Signatera, a tumor-informed MRD liquid biopsy test, and has been expanding into multi-cancer and treatment-selection assays. It is a direct competitor to Lucence's MRD-adjacent LiquidHALLMARK® applications and competes for the same oncologist customers.
Broad incumbents
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) offers FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for solid tumor profiling. It competes broadly with Lucence's LiquidHALLMARK® in tumor mutation profiling for therapy selection, and benefits from Roche's global commercial scale.
- Exact Sciences: Exact Sciences is a large molecular diagnostics company with the Cologuard colorectal screening test and Oncotype DX oncology franchise. It is a broad incumbent competing in adjacent oncology diagnostic categories and increasingly in liquid biopsy-based screening.
- NeoGenomics: NeoGenomics is a US-based oncology testing laboratory offering comprehensive solid tumor and liquid biopsy profiling services. It serves the same community oncologist and hospital customer base as Lucence, though with a broader multi-modal test menu.
Emerging players
- Personalis: Personalis offers NeXT Personal, a tumor-informed liquid biopsy MRD test for solid tumors. It is a more focused emerging player in liquid biopsy oncology, comparable in scale to Lucence and directly competing for the same oncology ordering physicians.
- Tempus: Tempus combines AI-driven molecular profiling with a large oncology data platform, offering both tissue and liquid biopsy assays (e.g., xT, xR). It overlaps with Lucence on AI-enabled tumor profiling and is a direct competitor in AI-augmented precision oncology.
- Caris Life Sciences: Caris offers MI Profile, a multi-platform molecular profiling assay (DNA/RNA) for solid tumors, including liquid biopsy options. It is comparable to Lucence on multiomic tumor profiling and competes for the same oncology and biopharma customers.
Regional players
- Burning Rock Biotech: Burning Rock is a China-based oncology diagnostics company offering next-generation sequencing-based liquid biopsy and tissue assays. It is comparable to Lucence in product portfolio and Asian-market orientation, though it primarily serves Greater China rather than Southeast Asia.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Lucence Diagnostics social profiles
Digital presenceLucence Diagnostics compliance and trust
Trust signalCompliance2 records
Lucence Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lucence Diagnostics leadership team
Management profileNumber of profiles
Lucence Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lucence Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lucence Diagnostics
What does Lucence Diagnostics do?
Lucence Diagnostics develops and commercializes ultrasensitive, non-invasive liquid biopsy diagnostic tests that analyze circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) from blood samples. Its portfolio supports cancer treatment selection (LiquidHALLMARK® and LiquidHALLMARK® CSF), multi-cancer early detection (LucenceINSIGHT®), and cardiovascular and leukemia risk evaluation through clonal hematopoiesis mutation detection (CardioHemeRISK™). All tests are powered by the company's proprietary AmpliMARK™ chemistry and mirror barcoding technology, processed through its CAP-accredited, CLIA-certified clinical laboratory.
Is Lucence Diagnostics a public or private company?
Lucence Diagnostics is a private company. It is classified as unknown and is currently operating.
When was Lucence Diagnostics founded?
Lucence Diagnostics was founded in 2016. It employs 11 to 50 people.
Where is Lucence Diagnostics based?
Lucence Diagnostics is headquartered in Palo Alto, United States, in the North America region.
How does Lucence Diagnostics make money?
Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are international Test Services and research Collaboration Services.
Who are Lucence Diagnostics's main competitors?
Direct peers on record are Guardant Health, GRAIL and Natera. Broad incumbents are Foundation Medicine, Exact Sciences and NeoGenomics. Emerging players are Personalis, Tempus and Caris Life Sciences. Burning Rock Biotech is listed as a regional player.
Does Lucence Diagnostics have an API?
No public API is recorded for Lucence Diagnostics.
What industry is Lucence Diagnostics in?
Lucence Diagnostics's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 8071.